National Institute of Allergy and Infectious Disease (NIAID) Funding for Studies of Hospital-Associated Bacterial Pathogens: Are Funds Proportionate to Burden of Disease?
详细信息 查看全文
- 作者：Seunghyug Kwon (1) (2)
Marin L Schweizer (1) (2) (3)
Eli N Perencevich (1) (2) (3) - 关键词：Antibiotic resistance ; NIH ; Hospital ; associated infection ; research funding ; disease burden
- 刊名：Antimicrobial Resistance and Infection Control
- 出版年：2012
- 出版时间：December 2012
- 年：2012
- 卷：1
- 期：1
- 全文大小：468KB
- 参考文献：1. Istook E: Research funding on major diseases is not proportionate to taxpayers' needs. / J NIH Res 1997,9(8):26鈥?.
2. Anderson C: NIH budget: A new kind of earmarking. / Science 1993,260(5107):483. CrossRef
3. Marshall E: Lobbyists seek to reslice NIH's pie. / Science 1997,276(5311):344鈥?. CrossRef
4. National Institutes of Health Working Group on Priority Setting: / Setting research priorities at the National Institutes of Health. Bethesda, MD: National Institutes of Health; 1997.
5. Committee on NIH Research Priority-Setting Process: Scientific opportunities and public needs: Improving priority setting and public input at the national institutes of health. 1998.
6. Klevens RM, Edwards JR, Richards CL Jr, Horan TC, Gaynes RP, Pollock DA, Cardo DM: Estimating health care-associated infections and deaths in U.S. hospitals, 2002. / Public Health Rep 2007,122(2):160鈥?.
7. Perencevich EN, Stone PW, Wright SB, Carmeli Y, Fisman DN, Cosgrove SE, Society for Healthcare Epidemiology of America: Raising standards while watching the bottom line: Making a business case for infection control. / Infect Control Hosp Epidemiol 2007,28(10):1121鈥?3. CrossRef
8. Rice LB: Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. / J Infect Dis 2008,197(8):1079鈥?1. CrossRef
9. Xu JQ, Kochanek KD, Murphy SL, Tejada-Vera B: / Deaths: Final data for 2007. National vital statistics reports. Hyattsville, MD: National Center for Health Statistics; 2010.
10. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK, Active Bacterial Core surveillance (ABCs) MRSA Investigators: Invasive methicillin-resistant Staphylococcus aureus infections in the United States. / JAMA 2007,298(15):1763鈥?1. CrossRef
11. National Institutes of Health National Institute of Allergy and Infectious Diseases: / Congresional justification. Bethesda, MD: National Institutes of Health; 2008.
12. Centers for Disease Control and Prevention: HIV surveillance report. [http://www.cdc.gov/hiv/topics/surveillance/resources/reports/] 2008.
13. Wenzel RP: The antibiotic pipeline--challenges, costs, and values. / N Engl J Med 2004,351(6):523鈥?. CrossRef
14. Projan SJ: Why is big pharma getting out of antibacterial drug discovery? / Curr Opin Microbiol 2003,6(5):427鈥?0. CrossRef
15. Carlet J, Collignon P, Goldmann D, Goossens H, Gyssens IC, Harbarth S, Jarlier V, Levy SB, N'Doye B, Pittet D, Richtmann R, Seto WH, van der Meer JW, Voss A: Society's failure to protect a precious resource: Antibiotics. / Lancet 2011,378(9788):369鈥?1. CrossRef
16. Burr CK, Lampe MA, Corle S, Margolin FS, Abresh C, Clark J, National Organizations' Collaborative to Eliminate Perinatal HIV in the US: An end to perinatal HIV: Success in the US requires ongoing and innovative efforts that should expand globally. / J Public Health Policy 2007,28(2):249鈥?0. CrossRef
17. Long EF, Owens DK: The cost-effectiveness of a modestly effective HIV vaccine in the United States. / Vaccine 2011,29(36):6113鈥?4. CrossRef
18. Bancroft EA: Antimicrobial resistance: It's not just for hospitals. / JAMA 2007,298(15):1803鈥?. CrossRef
19. Peters NK, Dixon DM, Holland SM, Fauci AS: The research agenda of the National Institute of Allergy and Infectious Diseases for antimicrobial resistance. / J Infect Dis 2008,197(8):1087鈥?3. CrossRef
20. FY2009 budget submission center for disease control and prevention discretionary all-purpose table [Internet] Available from: http://www.cdc.gov/fmo/fmofybudget.htm
21. Agency for Healthcare Research and Quality: / AHRQ's efforts to prevent and reduce healthcare-associated infections: FY2009 projects. Rockville, MD: Agency for Healthcare Research and Quality;
22. Panangala SV: U.S. Congressional Research Service. / Veterans medical care: FY2009 appropriations (RL34598; July 29, 2008) - 作者单位：Seunghyug Kwon (1) (2)
Marin L Schweizer (1) (2) (3)
Eli N Perencevich (1) (2) (3)
1. Iowa City Veterans Affairs Health Care System, Iowa City, IA, USA
2. Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, USA
3. Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, USA - ISSN：2047-2994
文摘
Background Hospital-associated infections (HAIs) are associated with a considerable burden of disease and direct costs greater than $17 billion. The pathogens that cause the majority of serious HAIs are Enterococcus faecium, Staphylococcus aureus, Clostridium difficile, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species, referred as ESCKAPE. We aimed to determine the amount of funding the National Institute of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) allocates to research on antimicrobial resistant pathogens, particularly ESCKAPE pathogens. Methods The NIH Research Portfolio Online Reporting Tools (RePORT) database was used to identify NIAID antimicrobial resistance research grants funded in 2007-2009 using the terms "antibiotic resistance," "antimicrobial resistance," and "hospital-associated infection." Results Funding for antimicrobial resistance grants has increased from 2007-2009. Antimicrobial resistance funding for bacterial pathogens has seen a smaller increase than non-bacterial pathogens. The total funding for all ESKCAPE pathogens was $ 22,005,943 in 2007, $ 30,810,153 in 2008 and $ 49,801,227 in 2009. S. aureus grants received $ 29,193,264 in FY2009, the highest funding amount of all the ESCKAPE pathogens. Based on 2009 funding data, approximately $1,565 of research money was spent per S. aureus related death and $750 of was spent per C. difficile related death. Conclusions Although the funding for ESCKAPE pathogens has increased from 2007 to 2009, funding levels for antimicrobial resistant bacteria-related grants is still lower than funding for antimicrobial resistant non-bacterial pathogens. Efforts may be needed to improve research funding for resistant-bacterial pathogens, particularly as their clinical burden increases.